newsfilter
← Latest News
GlobeNewswire·

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026Concluded last patient last visit in CANYON-1 Phase 1b study